Development of next generation Streptococcus pneumoniae vaccines conferring broad protection

Streptococcus pneumoniae is a major pathogen causing pneumonia with over 2 million deaths annually, especially in young children and the elderly. To date, at least 98 different pneumococcal capsular serotypes have been identified. Currently, the vaccines for prevention of S. pneumoniae infections a...

Full description

Bibliographic Details
Main Authors: Masomian, Malihe *, Zuleeza A, Gew, Lai Ti *, Poh, Chit Laa *
Format: Article
Language:English
Published: MDPI 2020
Subjects:
Online Access:http://eprints.sunway.edu.my/1302/
http://eprints.sunway.edu.my/1302/1/Malihe%20Development%20of%20Next%20Generation%20Streptococcus.pdf
_version_ 1848802022187335680
author Masomian, Malihe *
Zuleeza A,
Gew, Lai Ti *
Poh, Chit Laa *
author_facet Masomian, Malihe *
Zuleeza A,
Gew, Lai Ti *
Poh, Chit Laa *
author_sort Masomian, Malihe *
building SU Institutional Repository
collection Online Access
description Streptococcus pneumoniae is a major pathogen causing pneumonia with over 2 million deaths annually, especially in young children and the elderly. To date, at least 98 different pneumococcal capsular serotypes have been identified. Currently, the vaccines for prevention of S. pneumoniae infections are the 23-valent pneumococcal polysaccharide-based vaccine (PPV23) and the pneumococcal conjugate vaccines (PCV10 and PCV13). These vaccines only cover some pneumococcal serotypes and are unable to protect against non-vaccine serotypes and unencapsulated S. pneumoniae. This has led to a rapid increase in antibiotic-resistant non-vaccine serotypes. Hence, there is an urgent need to develop new, effective, and affordable pneumococcal vaccines, which could cover a wide range of serotypes. This review discusses the new approaches to develop effective vaccines with broad serotype coverage as well as recent development of promising pneumococcal vaccines in clinical trials. New vaccine candidates are the inactivated whole-cell vaccine strain (∆pep27∆comD mutant) constructed by mutations of specific genes and several protein-based S. pneumoniae vaccines using conserved pneumococcal antigens, such as lipoprotein and surface-exposed protein (PspA). Among the vaccines in Phase 3 clinical trials are the pneumococcal conjugate vaccines, PCV-15 (V114) and 20vPnC. The inactivated whole-cell and several protein-based vaccines are either in Phase 1 or 2 trials. Furthermore, the recent progress of nanoparticles that play important roles as delivery systems and adjuvants to improve the performance, as well as the immunogenicity of the nanovaccines, are reviewed.
first_indexed 2025-11-14T21:16:44Z
format Article
id sunway-1302
institution Sunway University
institution_category Local University
language English
last_indexed 2025-11-14T21:16:44Z
publishDate 2020
publisher MDPI
recordtype eprints
repository_type Digital Repository
spelling sunway-13022020-06-03T07:19:54Z http://eprints.sunway.edu.my/1302/ Development of next generation Streptococcus pneumoniae vaccines conferring broad protection Masomian, Malihe * Zuleeza A, Gew, Lai Ti * Poh, Chit Laa * QR355 Virology Streptococcus pneumoniae is a major pathogen causing pneumonia with over 2 million deaths annually, especially in young children and the elderly. To date, at least 98 different pneumococcal capsular serotypes have been identified. Currently, the vaccines for prevention of S. pneumoniae infections are the 23-valent pneumococcal polysaccharide-based vaccine (PPV23) and the pneumococcal conjugate vaccines (PCV10 and PCV13). These vaccines only cover some pneumococcal serotypes and are unable to protect against non-vaccine serotypes and unencapsulated S. pneumoniae. This has led to a rapid increase in antibiotic-resistant non-vaccine serotypes. Hence, there is an urgent need to develop new, effective, and affordable pneumococcal vaccines, which could cover a wide range of serotypes. This review discusses the new approaches to develop effective vaccines with broad serotype coverage as well as recent development of promising pneumococcal vaccines in clinical trials. New vaccine candidates are the inactivated whole-cell vaccine strain (∆pep27∆comD mutant) constructed by mutations of specific genes and several protein-based S. pneumoniae vaccines using conserved pneumococcal antigens, such as lipoprotein and surface-exposed protein (PspA). Among the vaccines in Phase 3 clinical trials are the pneumococcal conjugate vaccines, PCV-15 (V114) and 20vPnC. The inactivated whole-cell and several protein-based vaccines are either in Phase 1 or 2 trials. Furthermore, the recent progress of nanoparticles that play important roles as delivery systems and adjuvants to improve the performance, as well as the immunogenicity of the nanovaccines, are reviewed. MDPI 2020-03-17 Article PeerReviewed text en cc_by_nc_4 http://eprints.sunway.edu.my/1302/1/Malihe%20Development%20of%20Next%20Generation%20Streptococcus.pdf Masomian, Malihe * and Zuleeza A, and Gew, Lai Ti * and Poh, Chit Laa * (2020) Development of next generation Streptococcus pneumoniae vaccines conferring broad protection. Vaccines, 8 (1). p. 132. ISSN 2076-393X http://doi.org/10.3390/vaccines8010132 doi:10.3390/vaccines8010132
spellingShingle QR355 Virology
Masomian, Malihe *
Zuleeza A,
Gew, Lai Ti *
Poh, Chit Laa *
Development of next generation Streptococcus pneumoniae vaccines conferring broad protection
title Development of next generation Streptococcus pneumoniae vaccines conferring broad protection
title_full Development of next generation Streptococcus pneumoniae vaccines conferring broad protection
title_fullStr Development of next generation Streptococcus pneumoniae vaccines conferring broad protection
title_full_unstemmed Development of next generation Streptococcus pneumoniae vaccines conferring broad protection
title_short Development of next generation Streptococcus pneumoniae vaccines conferring broad protection
title_sort development of next generation streptococcus pneumoniae vaccines conferring broad protection
topic QR355 Virology
url http://eprints.sunway.edu.my/1302/
http://eprints.sunway.edu.my/1302/
http://eprints.sunway.edu.my/1302/
http://eprints.sunway.edu.my/1302/1/Malihe%20Development%20of%20Next%20Generation%20Streptococcus.pdf